Aimmune Therapeutics (AIMT) Reports In-Line Q3 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/1/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Aimmune Therapeutics (AIMT) Reports In-Line Q3 EPS

Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights

November 6, 2019 4:05 PM EST

--Webcast and conference call today at 4:30 p.m. ET--

BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2019 and provided operational highlights.

This is a transformative time for the company as we prepare to launch PALFORZIATM, our first drug candidate and potentially the first FDA-approved treatment for any food allergy. We were encouraged by the positive vote from the FDA APAC to... More